Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 14, 2026
DataAggregated Company Financials
Companies65
  • 7D-1.0%
  • 3M7.0%
  • 1Y8.7%
  • YTD-14.7%

Over the last 7 days, the Life Sciences industry has remained flat, although notably West Pharmaceutical Services gained 4.6%. The past year has been better, since the industry has gained 8.7% in that time. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 15 Jun 2026US$581.0bUS$150.6bUS$13.7b39.2x42.4x3.9x
Wed, 13 May 2026US$540.6bUS$150.3bUS$14.0b32x38.6x3.6x
Fri, 10 Apr 2026US$573.9bUS$147.8bUS$14.1b37.7x40.7x3.9x
Sun, 08 Mar 2026US$568.9bUS$147.8bUS$14.0b34.3x40.7x3.8x
Tue, 03 Feb 2026US$652.7bUS$147.0bUS$12.6b34.8x51.8x4.4x
Thu, 01 Jan 2026US$664.0bUS$145.8bUS$12.4b35.7x53.7x4.6x
Sat, 29 Nov 2025US$678.1bUS$145.8bUS$12.5b37x54.4x4.7x
Mon, 27 Oct 2025US$664.2bUS$145.3bUS$14.5b34.1x46x4.6x
Wed, 24 Sep 2025US$569.3bUS$144.3bUS$14.6b30.9x39.1x3.9x
Fri, 22 Aug 2025US$586.9bUS$144.1bUS$14.5b28.5x40.5x4.1x
Sun, 20 Jul 2025US$520.4bUS$142.9bUS$9.1b34.3x57x3.6x
Tue, 17 Jun 2025US$526.1bUS$142.9bUS$9.2b36.4x57.4x3.7x
Thu, 15 May 2025US$529.4bUS$142.7bUS$9.0b33.7x58.6x3.7x
Sat, 12 Apr 2025US$497.6bUS$142.6bUS$10.0b34.6x50x3.5x
Mon, 10 Mar 2025US$611.4bUS$143.1bUS$9.8b42.5x62.7x4.3x
Wed, 05 Feb 2025US$679.6bUS$143.1bUS$10.4b39.7x65.4x4.8x
Fri, 03 Jan 2025US$651.1bUS$142.4bUS$10.2b42.6x63.7x4.6x
Sun, 01 Dec 2024US$672.6bUS$142.4bUS$10.2b44.5x65.7x4.7x
Tue, 29 Oct 2024US$674.4bUS$142.0bUS$8.3b36.2x81.6x4.7x
Thu, 26 Sep 2024US$745.5bUS$141.8bUS$8.5b36.8x87.7x5.3x
Sat, 24 Aug 2024US$738.0bUS$141.8bUS$8.5b37.4x87.2x5.2x
Mon, 22 Jul 2024US$675.6bUS$141.2bUS$12.2b39.9x55.3x4.8x
Wed, 19 Jun 2024US$694.2bUS$141.3bUS$12.2b38.6x57x4.9x
Fri, 17 May 2024US$744.4bUS$141.5bUS$12.6b38.7x59.3x5.3x
Sun, 14 Apr 2024US$725.5bUS$142.0bUS$12.8b42.3x56.7x5.1x
Tue, 12 Mar 2024US$753.4bUS$142.2bUS$12.8b44.2x59x5.3x
Thu, 08 Feb 2024US$715.4bUS$141.9bUS$12.8b39x55.7x5x
Sat, 06 Jan 2024US$689.0bUS$153.9bUS$14.2b36.1x48.6x4.5x
Mon, 04 Dec 2023US$651.8bUS$153.8bUS$14.0b35.5x46.5x4.2x
Wed, 01 Nov 2023US$572.6bUS$153.7bUS$11.2b29.7x51.3x3.7x
Fri, 29 Sep 2023US$670.3bUS$154.6bUS$11.2b33.1x59.8x4.3x
Sun, 27 Aug 2023US$712.7bUS$154.6bUS$11.2b32.9x63.6x4.6x
Tue, 25 Jul 2023US$744.7bUS$155.5bUS$12.7b29.5x58.7x4.8x
Thu, 22 Jun 2023US$691.0bUS$152.4bUS$12.5b29.2x55.3x4.5x
Price to Earnings Ratio

55.3x


Total Market Cap: US$691.0bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.4x which is lower than its 3-year average PE of 56.3x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.1% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.87%
Healthcare0.88%
Life Sciences-0.96%
Clinical Research and Equipment-0.96%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
WST West Pharmaceutical ServicesUS$328.824.6%
+US$1.0b		48.2%PE42.8x
RGEN RepligenUS$130.596.8%
+US$467.1m		2.4%PE143.3x
MEDP Medpace HoldingsUS$467.342.9%
+US$373.8m		56.7%PE29x
TECH Bio-TechneUS$54.003.9%
+US$314.7m		6.9%PE77.2x
CRL Charles River Laboratories InternationalUS$187.513.4%
+US$297.2m		25.5%PS2.2x

Latest News

RGEN
US$130.59
Repligen
7D
6.8%
1Y
2.4%
Narrative Update • Jun 13

RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance

Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.
TEM
US$47.82
Tempus AI
7D
3.0%
1Y
-32.9%
Narrative Update • Jun 13

TEM: FDA Progress And Data Platforms Will Drive Future Oncology Demand

Tempus AI's analyst price targets have shifted lower to around $66.53, reflecting a mix of downward revisions and more cautious views on long term monetization from several firms, even as others acknowledge the company's differentiated data offering. Analyst Commentary Recent research paints a mixed picture around Tempus AI, with views split on how quickly the company can translate its differentiated data assets into predictable cash flows and what that should mean for valuation.
A
US$129.84
Agilent Technologies
7D
-4.1%
1Y
10.9%
DHR
US$180.10
Danaher
7D
-2.3%
1Y
-10.3%
BRKR
US$54.23
Bruker
7D
-3.8%
1Y
41.6%
Narrative Update • Jun 11

BRKR: Semiconductor And Diagnostics Momentum Will Balance Helium And Execution Risks

The updated analyst price target for Bruker has moved from an implied fair value of $49.15 to $53.25, reflecting recent target hikes into the $65 range by several firms as analysts incorporate refreshed models, sector sentiment, and valuation concerns into their views. Analyst Commentary Recent research updates show a mix of optimism and caution around Bruker, with price targets clustering around US$65 alongside more neutral stances that focus on valuation and operating risks.
STVN
US$17.08
Stevanato Group
7D
-7.5%
1Y
-27.3%
Seeking Alpha • Jun 11

Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside

Summary Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes. Margin expansion, operational leverage from new facilities, and growth are not well reflected in the current valuation. We reiterate our buy rating. Read the full article on Seeking Alpha
AVTR
US$9.39
Avantor
7D
2.5%
1Y
-28.2%
WAT
US$355.53
Waters
7D
-2.7%
1Y
3.9%
TMO
US$469.34
Thermo Fisher Scientific
7D
-0.7%
1Y
16.5%
Narrative Update • Jun 09

TMO: AI Tools And Proteomics Platforms Will Drive Future Upside

Thermo Fisher Scientific's updated fair value estimate has moved down from about $738 to $721 per share as analysts temper longer term revenue growth assumptions, partly reflecting recent price target cuts and more cautious views on organic growth momentum, even as they acknowledge that the company's margin profile and P/E remain supportive. Analyst Commentary Recent Street research paints a mixed picture for Thermo Fisher Scientific, with some analysts turning more cautious on near term organic growth while others highlight the stock as a core holding for exposure to life science tools.
WST
US$328.82
West Pharmaceutical Services
7D
4.6%
1Y
48.2%
TECH
US$54.00
Bio-Techne
7D
3.9%
1Y
6.9%
MEDP
US$467.34
Medpace Holdings
7D
2.9%
1Y
56.7%
IQV
US$181.46
IQVIA Holdings
7D
-1.1%
1Y
15.7%
SHC
US$16.19
Sotera Health
7D
3.6%
1Y
41.6%
Narrative Update • Jun 04

SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside

Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.
MTD
US$1,131.49
Mettler-Toledo International
7D
-2.0%
1Y
-2.1%
Narrative Update • Jun 03

MTD: Automation And Emerging Markets Will Support EPS Upside Despite Geopolitical Risks

Analysts have trimmed their average price target for Mettler-Toledo International from about $1,344.50 to roughly $1,327.83. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations.
CRL
US$187.51
Charles River Laboratories International
7D
3.4%
1Y
25.5%
Narrative Update • Jun 03

CRL: Rich Multiple And Margin Pressure Will Likely Cap AI Upside

Analysts have lifted the fair value estimate for Charles River Laboratories International by about $6.81 per share to $154.56, citing a more supportive regulatory backdrop for cross-border biotech work and expectations that divesting lower margin operations could improve overall earnings quality. Analyst Commentary Recent research commentary on Charles River Laboratories International has leaned more constructive on the regulatory backdrop for cross-border biotech work and on the potential earnings mix shift from divesting lower margin activities.